✨
AI Summary & Key Takeaways
AI Insight⚡ TL;DR(Too Long; Didn't Read)
In this report, the effect of approximately 1 year of progesterone treatment in a patient with LAM, presenting with recurrent pneumothorax, was evaluated.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Lymphangioleiomyomatosis (LAM) is a rare interstitial lung disease.
📊
Key Findings & Data:Patients with LAM generally present with dyspnea and spontaneous pneumothorax.
💡
Conclusion & Impact:In this report, the effect of approximately 1 year of progesterone treatment in a patient with LAM, presenting with recurrent pneumothorax, was evaluated.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Lymphangioleiomyomatosis (LAM) is a rare interstitial lung disease. Patients with LAM generally present with dyspnea and spontaneous pneumothorax. Today, while there is no proven medical treatment method for LAM, progesterone is among the widely used drugs. In this report, the effect of approximately 1 year of progesterone treatment in a patient with LAM, presenting with recurrent pneumothorax, was evaluated.
🔖
Cite This Article
TÜLEK, B., KANAT, F., SÜERDEM, M. (2014). Progesterone Treatment Experience in a Patient with Lymphangioleiomyomatosis Presenting with Recurrent Pneumothorax. Solunum, Cilt: 16 - Sayı: 3, 199–202. https://ajindex.com/articles/314322